Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
American Brivision Corp
(OP:
ABVC
)
6.600
USD
UNCHANGED
Streaming Delayed Price
/ Updated:
9:32 AM EST, Dec 4, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
6.600
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
6.600
Today's Range
6.600 - 6.600
52wk Range
1.250 - 20.00
Shares Outstanding
213,926,475
Dividend Yield
N/A
Performance
YTD
+214.29%
+214.29%
1 Month
+26.92%
+26.92%
3 Month
-22.35%
-22.35%
6 Month
-56.00%
-56.00%
1 Year
+340.00%
+340.00%
Top News
More News
American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
Today 8:36 EST
from
NewMediaWire
American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
Today 8:31 EST
from
GlobeNewswire News Releases
More News
Read More
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 14, 2019
from
NewMediaWire
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 14, 2019
from
GlobeNewswire News Releases
American BriVision Highlights Results from Vitargus(R) First-in-Human Clinical Trial
October 15, 2019
from
NewMediaWire
American BriVision Highlights Results from Vitargus® First-in-Human Clinical Trial
October 15, 2019
from
GlobeNewswire News Releases
American BriVision Announces Vitargus® Presentation at Upcoming AAO 2019 Annual Meeting
October 10, 2019
from
GlobeNewswire News Releases
American BriVision Announces Vitargus(R) Presentation at Upcoming AAO 2019 Annual Meeting
October 10, 2019
from
NewMediaWire
American BriVision Appoints Chihliang "Andy" An as New Chief Financial Officer
October 08, 2019
from
NewMediaWire
American BriVision Appoints Chihliang "Andy" An as New Chief Financial Officer
October 08, 2019
from
GlobeNewswire News Releases
American BriVision Issues Corrective Press Release on Strategic Collaboration with BioLite Japan
September 18, 2019
from
NewMediaWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
